Yaqing Cao

CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease

T. Sui, Mingfeng Zhao, Wenyi Lu, 2021, Cancer Immunology, Immunotherapy.

HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation

Xiaoyuan He, Lin Cheng, Mingfeng Zhao, 2019, Leukemia.

Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma

Xiaoyuan He, Mingfeng Zhao, Wenyi Lu, 2019, Front. Oncol..

Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL

Xiaoyuan He, Kai-qi Liu, Mingfeng Zhao, 2019, Leukemia.

Targeting Bcl-2 Proteins in Acute Myeloid Leukemia

Mingfeng Zhao, Wenyi Lu, X. Jin, 2020, Frontiers in Oncology.

Umbilical cord blood-derived mesenchymal stromal cells promote myeloid-derived suppressor cell proliferation by secreting HLA-G to reduce acute graft-versus-host disease after hematopoietic stem cell transplantation.

Mingfeng Zhao, Wenyi Lu, Xia Xiao, 2020, Cytotherapy.

Rapid and simultaneous determination of ten anti-tuberculosis drugs in human plasma by UPLC-MS/MS with applications in therapeutic drug monitoring.

L. Ai, Yanzhen Han, Xiangji Wang, 2020, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Identification of immune subtypes of Ph-neg B-ALL with ferroptosis related genes and the potential implementation of Sorafenib

A. Sun, Ling Zhang, Suning Chen, 2021, BMC Cancer.